In addition to the purchase of a company by means of an asset deal, there is lso a second basic form of a company acquisition, namely the acquisition of an interest. A purchase of shares takes place if a company is sold in its present form, normally an unlimited partnership under commercial law or a joint stock company. All that is sold from a legal point of view is the interest of the seller in the company. This is represented by the partners' shares in the case of an unlimited partnership or shares in a private limited company(GmbH) or a public limited company (AG) in the case of a joint stock company. The legal form remains the same therefore and only the shareholdings are changed. The main differences between a share deal and asset deal are explained in the following comments. It should first of all be differentiated whether the interest is being acquired in an unlimited partnership or in a joint stock company as different legal regulations apply in both cases.
For further information please contact Dr Erich Michel, Wessing Berenberg-Gossler Zimmermann Lange, Freiherr-Vom-Stein-Strasse 24-26, Frankfurt am Maim 60323, Frankfurt, Germany- Tel: +496 997 1300, Fax: +496 997 130100.
You may also wish to read through related Wessing Berenberg-Gossler Zimmermann Lange. You can view the entire archive via the Internet on Business Monitor Online (http://www.businessmonitor.co.uk), or via your online provider by entering "Wessing Berenberg-Gossler Zimmermann Lange" and "Business Monitor" as a free text search.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
In this section, we give a factual overview of a significant case development at EU level, and then provide a more detailed analysis of the important substantive and procedural developments addressed in this case.
Sayenko Kharenko's antitrust team has provided legal assistance in obtaining merger clearance with the Antimonopoly Committee of Ukraine (the "AMC") for the EUR 22.8 billion acquisition of Sanofi's animal health (AH) business ("Merial") by Boehringer Ingelheim through an asset swap in exchange for Boehringer Ingelheim's consumer healthcare (CHC) business.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).